AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

5 stories found

A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters01

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
A doctor and patient in a clinical corridor stand near a medical device shown under ongoing monitoring.
Social good & healthUnited Kingdom+2 clusters02

The UK accepts 44 medical-AI recommendations. Now it must prove the monitoring works

The UK government has accepted all 44 recommendations from an independent commission on regulating AI in healthcare. That is a policy commitment, not 44 rules that have already taken effect or proof that an AI product improves patients' health. The most concrete change today is the opening of Phase 3 of the MHRA's AI Airlock, a regulatory sandbox focused on post-market surveillance and how AI-enabled devices behave after deployment. The commission's central critique is that one-time assessment is not enough for technology that changes, drifts or meets different patients and clinical workflows. The government promises draft guidance by December 2026 on managing changes to AI-enabled medical devices and a full implementation roadmap by spring 2027. It also plans future consultation on how devices are classified. The application terms expose an important implementation question: participation has no fee, but applicants currently fund their own studies and data access, and testing in real settings remains in a shadow pathway rather than directly informing patient decisions. That can be a sensible safety design; it may also be harder for smaller developers to finance, although participation data do not yet show exclusion. Patients should ask whether monitoring will detect unequal performance, how clinicians will report failures, who can pause an update, and whether results will be public. Healthcare AI's promise is real enough to warrant testing. The hard work starts after a policy announcement: measure outcomes over time, name the accountable institution, and show what happens when the system changes under care.

6 min
A radiology scan passes through separate European and United States regulatory gates while two clocks show sharply different waits and shared evidence remains visible between them.
Social good & healthEuropean Union and United States+2 clusters03

Radiology AI faces a 14-month transatlantic approval gap

A peer-reviewed npj Digital Medicine study analyzed 239 AI-enabled radiology software devices with a European CE mark, United States Food and Drug Administration clearance, or both. Of the sample, 128 had only a CE mark, 95 received a CE mark before FDA clearance, and 16 received FDA clearance first. Among dual-authorized devices, the median wait for the second authorization was 17.5 months when the CE mark came first, compared with 3.5 months when FDA clearance came first. Radiograph-interpretation software was associated with a longer wait, while European Class IIa classification was associated with a shorter interval. The observational study identifies sequencing and association; it does not establish why every delay occurred or that one regulator's decision is superior. Its policy value is the asymmetry. Developers, hospitals, and regulators need clearer, comparable evidence requirements so validated safety information can travel across jurisdictions without converting coordination into weaker scrutiny.

5 min
A wearable bioelectronic patch linking biosensing, an AI decision node, human oversight, and controlled therapy in a closed loop.
Social good & healthGlobal+2 clusters04

Gao et al., “AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare”

A Nature Sensors review argues that AI-powered closed-loop wearables could move healthcare devices beyond passive data collection by connecting continuous biosensing directly to AI-guided decisions and therapeutic intervention. The authors emphasize that clinical value depends on the coordinated system—sensing, control, treatment, and human oversight—not any component alone. Long-term interface stability, robust control, transparent safety mechanisms, and evidence of patient benefit remain prerequisites for scalable use.

3 min
Cognition & learningGlobal+1 clusters05

Mayourian et al., “Single lead electrocardiographic detection of left ventricular systolic dysfunction in pediatric and congenital heart disease”

Researchers affiliated with Harvard Medical School, the University of Pennsylvania, and the University of Toronto developed a noise-adapted single-lead ECG model for detecting left-ventricular systolic dysfunction in pediatric and congenital-heart-disease populations. The study used an internal cohort of 70,226 patients and external cohorts comprising 42,984 patients at Children’s Hospital of Philadelphia and 284 patients at Toronto General Hospital, reporting strong performance across different congenital conditions, age groups, racial groups, and health systems.

2 min